Swedbank AB Has $57.78 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Swedbank AB cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 19.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 780,486 shares of the medical research company’s stock after selling 189,026 shares during the quarter. Swedbank AB owned about 0.13% of Edwards Lifesciences worth $57,779,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Algert Global LLC grew its holdings in Edwards Lifesciences by 38.4% in the second quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock worth $426,000 after purchasing an additional 1,280 shares during the period. NewEdge Advisors LLC grew its holdings in Edwards Lifesciences by 33.5% in the second quarter. NewEdge Advisors LLC now owns 71,059 shares of the medical research company’s stock worth $6,564,000 after purchasing an additional 17,841 shares during the period. SPC Financial Inc. acquired a new stake in Edwards Lifesciences in the second quarter worth $213,000. New Century Financial Group LLC grew its holdings in Edwards Lifesciences by 34.2% in the second quarter. New Century Financial Group LLC now owns 3,579 shares of the medical research company’s stock worth $331,000 after purchasing an additional 912 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Edwards Lifesciences in the second quarter worth $8,917,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Morgan Stanley restated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Robert W. Baird dropped their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $71.21 on Thursday. The firm has a market cap of $42.00 billion, a price-to-earnings ratio of 10.28, a P/E/G ratio of 3.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm’s 50-day simple moving average is $72.37 and its two-hundred day simple moving average is $70.06.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,000 shares of company stock valued at $2,195,180. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.